Results 1 to 10 of about 80,781 (141)

Synthesis and Discovery of Ligustrazine–Heterocycle Derivatives as Antitumor Agents

Frontiers in Chemistry, 2022
Ligustrazine (TMP) is a natural pyrazine alkaloid extracted from the roots of Ligusticum Chuanxiong Hort, which has the potential as an antitumor agent.
Shitang Ma, Shitang Ma, Shitang Ma, Ning Zhang, Jiafu Hou, Shijuan Liu, Jiawen Wang, Baowei Lu, Fucheng Zhu, Peipei Wei, Ge Hong, Tianjun Liu   +11 more
doaj   +2 more sources

Repurposing dronedarone induces ferroptosis through GPX4 inactivation and degradation in pancreatic cancer [PDF]

Journal of Experimental & Clinical Cancer Research
Background Pancreatic cancer is an aggressive malignancy with poor prognosis and frequent resistance to standard anticancer therapies, highlighting the need for treatments that more effectively induce tumor cell death.
Yanmei Gu, Yingying Wang, Gangli Liu, Rong Cui, Chenzhe Ma, Jianrong Wang, Xing Gao, Yang Zhao, Yumin Li   +8 more
doaj   +2 more sources

Comparative Analysis of 3D Bladder Tumor Spheroids Obtained by Forced Floating and Hanging Drop Methods for Drug Screening

Frontiers in Physiology, 2017
Introduction: Cell-based assays using three-dimensional (3D) cell cultures may reflect the antitumor activity of compounds more accurately, since these models reproduce the tumor microenvironment better.Methods: Here, we report a comparative analysis of ...
Robson L. F. Amaral, Mariza Miranda, Priscyla D. Marcato, Kamilla Swiech   +3 more
doaj   +2 more sources

Synergisms of genome and metabolism stabilizing antitumor therapy (GMSAT) in human breast and colon cancer cell lines: a novel approach to screen for synergism

BMC Cancer, 2020
Background Despite an improvement of prognosis in breast and colon cancer, the outcome of the metastatic disease is still severe. Microevolution of cancer cells often leads to drug resistance and tumor-recurrence.
Jérôme Ruhnau, Jonas Parczyk, Kerstin Danker, Britta Eickholt, Andreas Klein   +4 more
doaj   +3 more sources

Antitumor activities of Aspiletrein A, a steroidal saponin from Aspidistra letreae, on non-small cell lung cancer cells

BMC Complementary Medicine and Therapies, 2021
Background Lung cancer is one of the leading causes of death worldwide due to its strong proliferative and metastatic capabilities. The suppression of these aggressive behaviors is of interest in anticancer drug research and discovery.
Hien Minh Nguyen, Hoai Thi Nguyen, Suthasinee Seephan, Hang Bich Do, Huy Truong Nguyen, Duc Viet Ho, Varisa Pongrakhananon   +6 more
doaj   +2 more sources

Discovery of a pyrrole-pyridinimidazole derivative as novel SIRT6 inhibitor for sensitizing pancreatic cancer to gemcitabine

Cell Death and Disease, 2023
Pancreatic cancer is a highly aggressive cancer, and is primarily treated with gemcitabine, with increasing resistance. SIRT6 as a member of sirtuin family plays important roles in lifespan and diverse diseases, such as cancer, diabetes, inflammation and
Nannan Song, Xian Guan, Siqi Zhang, Yanqing Wang, Xuekai Wang, Zhongxia Lu, Daochen Chong, Jennifer Yiyang Wang, Rilei Yu, Wengong Yu, Tao Jiang, Yuchao Gu   +11 more
doaj   +2 more sources

Repurposing the Antibacterial Activity of the Drug Teniposide Against Gram-Positive Bacteria

Cellular Microbiology
Drug repurposing is sparking considerable interest due to reduced costs and development times. The current study details the screening of teniposide, an antitumor drug, for its antibacterial activity against both Gram-positive and Gram-negative strains ...
Federica Dell’Annunziata, Veronica Folliero, Roberta Della Marca, Francesca Palma, Giuseppina Sanna, Anna De Filippis, Pasquale Pagliano, Aldo Manzin, Gianluigi Franci, Massimiliano Galdiero   +9 more
doaj   +2 more sources

Targeting of focal adhesion kinase enhances the immunogenic cell death of PEGylated liposome doxorubicin to optimize therapeutic responses of immune checkpoint blockade

Journal of Experimental & Clinical Cancer Research
Backgrounds Immune checkpoint blockade (ICB) is widely considered to exert long-term treatment benefits by activating antitumor immunity. However, many cancer patients show poor clinical responses to ICB due in part to the lack of an immunogenic niche ...
Baoyuan Zhang, Ning Li, Jiaming Gao, Yuxi Zhao, Jun Jiang, Shuang Xie, Cuiping Zhang, Qingyu Zhang, Leo Liu, Zaiqi Wang, Dongmei Ji, Lingying Wu, Ruibao Ren   +12 more
doaj   +2 more sources

Machine learning-aided discovery of T790M-mutant EGFR inhibitor CDDO-Me effectively suppresses non-small cell lung cancer growth

Cell Communication and Signaling
Background Epidermal growth factor receptor (EGFR) T790M mutation often occurs during long durational erlotinib treatment of non-small cell lung cancer (NSCLC) patients, leading to drug resistance and disease progression.
Rui Zhou, Ziqian Liu, Tongtong Wu, Xianwei Pan, Tongtong Li, Kaiting Miao, Yuru Li, Xiaohui Hu, Haigang Wu, Andrew M. Hemmings, Beier Jiang, Zhenzhen Zhang, Ning Liu   +12 more
doaj   +2 more sources

RESEARCH PROGRESS IN INDIVIDUALIZED DRUG SCREENING TECHNOLOGY FOR PATIENTS WITH TUMORS [PDF]

精准医学杂志, 2023
In China, the incidence of tumors is increasing year by year, with the number of patients with new tumors ranking first in the world. Currently, tumors are usually treated with surgery combined with radiotherapy, chemotherapy, targeted therapy, or ...
WU Xiao-xiao, LIU Meiyou, PENG Li, CHENG Lianghua, WANG Fan, WANG Jingwen, JIA Yanyan
doaj   +1 more source